艾美赛珠单抗(Emicizumab) - 药物靶点：F10 x factor IXa_在研适应症：凝血因子缺乏症，血友病A，关节积血_专利_临床

概要

基本信息

药物类型

双特异性抗体

别名

Anti-factor IXa anti-factor X humanized bispecific antibody、Emicizumab (Genetical Recombination)、Emicizumab (genetical recombination) (JAN)

+ [13]

靶点

F10 x factor IXa

作用机制

F10抑制剂(凝血因子X抑制剂)、factor IXa抑制剂(激活型凝血因子IX抑制剂)

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病+ [1]

在研适应症

凝血因子缺乏症血友病A关节积血+ [2]

非在研适应症-

原研机构

Chugai Pharmaceutical Co., Ltd.

在研机构

Hoffmann-La Roche, Inc.University of Chulalongkorn

罗氏（中国）投资有限公司

+ [6]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2017-11-16),

血友病A

最高研发阶段(中国)批准上市

特殊审评突破性疗法 (美国)、孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)

登录后查看首次获批时间轴

序列信息

Sequence Code 5386H

来源: *****

Sequence Code 5425H

来源: *****

Sequence Code 5467L

来源: *****

关联

75

项与艾美赛珠单抗相关的临床试验

NCT05248594 / Not yet recruitingN/AIIT

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

We have developed a questionnaire to elucidate the dosing, frequency and indication for the use of emicizumab in patients with Hemophilia A (mild, moderate or severe) ages 0-3 years. We are also collecting data on any pre-, peri and post surgical practices while on emicizumab. More importantly, we are asking if pediatricians are planning to introduce factor 8 to children who are already on emicizumab for primary prophylaxis as well as how and when they are planning to do so. We hope that this data will help inform understanding of current use of emicizumab in infants and young children as a form of primary prophylaxis, especially when venous access has historically been a limiting factor.

开始日期2024-08-01

申办/合作机构

Montefiore Medical Center

[+1]

NCT06145373 / Recruiting临床1期

An Open-label, Single-arm Treatment Study to Investigate the Safety and Tolerability of Switching From Emicizumab to Fitusiran Prophylaxis in Male Participants Aged ≥18 Years of Age With Severe Hemophilia A, With or Without Inhibitors

This is an exploratory, single group, Phase 1, 1-arm study to assess treatment with fitusiran prophylaxis after switching from emicizumab prophylaxis.
This study aims to evaluate the safety and tolerability of switching to fitusiran after a transition period from the last dose of emicizumab. The study will be conducted in male participants with severe hemophilia A, with or without inhibitors, aged ≥18 years, who were previously receiving emicizumab prophylaxis.
Study details include:
The study duration will be up to approximately 28 months:
There will be an approximately 2-month screening period.
There will be a transition period before fitusiran treatment starts (pre-fitusiran treatment period)
The fitusiran treatment duration will be up to 18-months (fitusiran treatment period)
The antithrombin (AT) follow-up (FU) period will be up to 6 months after the last dose of fitusiran (during which the AT activity level will be monitored at approximately monthly intervals following the final fitusiran dose until AT activity levels return to at least 60%).
The study site visits are scheduled at monthly/ every 2 months intervals of 28 days (4 weeks) / 56 days (8 weeks), respectively, during the fitusiran treatment period.

开始日期2024-03-01

申办/合作机构

Sanofi

CTRI/2024/01/061593 / Recruiting临床4期

Evaluation of efficacy and safety of low dose versus standard dose Emicizumab for the treatment of Hemophilia A – A randomized controlled trial - Nil

开始日期2024-01-22

申办/合作机构-

100 项与艾美赛珠单抗相关的临床结果

登录后查看更多信息

100 项与艾美赛珠单抗相关的转化医学

登录后查看更多信息

100 项与艾美赛珠单抗相关的专利（医药）

登录后查看更多信息

531

项与艾美赛珠单抗相关的文献（医药）

2024-04-04·Blood

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial

Article

作者: Buri, Muriel ; Young, Guy ; Deb, Sonia ; Pipe, Steven W ; Oldenburg, Johannes ; Kiialainen, Anna ; Dhalluin, Christophe ; Schmitt, Christophe ; Niggli, Markus ; Collins, Peter ; Jiménez-Yuste, Víctor ; Chang, Tiffany ; Peyvandi, Flora ; Mancuso, Maria Elisa ; Lehle, Michaela ; Fijnvandraat, Karin ; Kavakli, Kaan ; Kenet, Gili

Abstract:

Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated to infants, designed to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in those aged ≤12 months with severe HA without factor VIII (FVIII) inhibitors. Participants in this phase 3b trial received emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks and are continuing emicizumab during the 7-year long-term follow-up. Efficacy end points included annualized bleed rate (ABR): treated, all, treated spontaneous, and treated joint bleeds. Safety end points included adverse events (AEs), thromboembolic events (TEs), thrombotic microangiopathies (TMAs), and immunogenicity (anti-emicizumab antibodies [ADAs] and FVIII inhibitors). At primary analysis, 55 male participants had received emicizumab (median treatment duration: 100.3; range, 52-118 weeks). Median age at informed consent was 4.0 months (range, 9 days to 11 months 30 days). Model-based ABR for treated bleeds was 0.4 (95% confidence interval, 0.30–0.63), with 54.5% of participants (n = 30) having zero treated bleeds. No ICH occurred. All 42 treated bleeds in 25 participants (45.5%) were traumatic. Nine participants (16.4%) had ≥1 emicizumab-related AE (all grade 1 injection-site reactions). No AE led to treatment changes. No deaths, TEs, or TMAs occurred. No participant tested positive for ADAs. Two participants were confirmed positive for FVIII inhibitors. This primary analysis of HAVEN 7 indicates that emicizumab is efficacious and well tolerated in infants with severe HA without FVIII inhibitors.

2024-04-01·Journal of thrombosis and haemostasis : JTH

Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients

Article

作者: Jijina, Farah ; Shanmukhaiah, Chandrakala ; Patil, Kirti ; Madkaikar, Manisha ; Gogtay, Nithya J ; Patil, Rucha ; Pandey, Puloma

BACKGROUND:

Low-dose emicizumab can potentially offer a cost-effective treatment option in persons with hemophilia A, especially in developing countries.

OBJECTIVES:

To compare the efficacy and safety of low-dose emicizumab with those on low-dose factor (F)VIII prophylaxis via chart review.

METHODS:

After ethics approval, chart data of 2 groups of patients were reviewed: group 1 (low-dose emicizumab, n = 10; 3 mg/kg monthly without a loading dose) and group 2 (low-dose FVIII prophylaxis, n = 10; 10-20 IU/kg of FVIII concentrates twice a week). Outcomes were target joints, annual bleeding rate, annual joint bleeding rate, Hemophilia Joint Health Score, nonactivated thromboelastometry-rotational thromboelastometry clotting time, plasma emicizumab levels, and direct costs of treatment.

RESULTS:

All outcome measures were significantly better in the low-dose emicizumab group than in the low-dose FVIII prophylaxis group. For nonactivated thromboelastometry-rotational thromboelastometry, median values after 6 months in the low-dose emicizumab group were comparable with values seen in patients with mild hemophilia, while the values in the low-dose FVIII prophylaxis group were similar to those of patients with moderate hemophilia. The direct cost of low-dose emicizumab was found to be approximately US $6000 and that for low-dose recombinant FVIII prophylaxis used in our study was US $6282 (the cost may range from US $3432 to $7920 depending on the type of factor) when compared to approximately US $15 000 for standard-dose emicizumab.

CONCLUSION:

Low-dose emicizumab offers a cost-effective treatment option and can improve access in developing countries. These findings need to be confirmed in a larger and better-controlled study.

2024-04-01·Journal of thrombosis and haemostasis : JTH

FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic

Article

作者: Lopez-Jaime, Francisco J ; Windyga, Jerzy ; Matytsina, Irina ; Mahlangu, Johnny ; Chowdary, Pratima ; Nielsen, Anne Louise ; Lentz, Steven R ; Gil, Lidia

BACKGROUND:

Mim8 (denecimig) is a factor VIII (FVIII) mimetic bispecific antibody in development for the treatment of hemophilia. Data from the phase 1 part of FRONTIER1 (EudraCT: 2019-000465-20, NCT04204408, and NN7769-4513) suggested that Mim8 was well tolerated in healthy participants and exhibited pharmacokinetic (PK) properties consistent with dose proportionality.

OBJECTIVES:

The partially randomized, phase 2, multiple ascending dose (MAD) part of FRONTIER1 aimed to evaluate the safety, PK, pharmacodynamics (PD), and exploratory efficacy of Mim8 in participants with hemophilia A with or without FVIII inhibitors.

METHODS:

The MAD part of FRONTIER1 consisted of 42 participants, assigned to 5 cohorts, with participants in cohorts 3 and 4 randomized 1:1 to dosing weekly or every 4 weeks, respectively. Four of the 42 participants (9.5%) had FVIII inhibitors prior to study enrolment. The primary endpoint was treatment-emergent adverse events (TEAEs). PK and PD were evaluated by Mim8 plasma concentration and thrombin generation, respectively. Exploratory efficacy was assessed via the number of treated bleeds. Safety and PD parameters were also evaluated from an exploratory cohort treated with emicizumab.

RESULTS:

Mim8 was well tolerated, with 1 serious TEAE (anxiety-related chest pain) deemed unrelated to Mim8. There was no dose dependency on the number, causality, type, or severity of TEAEs. PK/PD properties supported weekly to monthly dosing approaches, and few participants experienced treated bleeds beyond the lowest dose cohort (1 in cohorts 2 and 3, and 3 in cohort 5).

CONCLUSION:

These data support the continued clinical development of Mim8, and FRONTIER1 has proceeded onto an extension phase.

291

项与艾美赛珠单抗相关的新闻（医药）

2024-07-01

·drugs

ISTH Issues Clinical Practice Guideline for the Treatment of Hemophilia

MONDAY, July 1, 2024 -- In a clinical practice guideline issued by the International Society on Thrombosis and Haemostasis and published online June 13 in the Journal of Thrombosis and Haemostasis , recommendations are presented for the treatment of congenital hemophilia. Suely M. Rezende, M.D., Ph.D., from the Universidade Federal de Minas Gerais in Belo Horizonte, Brazil, and colleagues developed an evidence-based clinical practice guideline for hemophilia treatment. Thirteen questions were selected by a multidisciplinary panel: 11 addressed the treatment of hemophilia A and two addressed hemophilia B treatment. For hemophilia A, the panel addressed questions relating to prophylactic and episodic treatment with factor VIII concentrates, bypassing agents, nonfactor therapy (emicizumab) (with and without inhibitors), as well as immune tolerance induction. Questions on prophylactic and episodic treatment of bleeding events with factor IX concentrates were addressed for hemophilia B. For all 13 recommendations, agreement was reached. For severe and moderately severe hemophilia A and B without inhibitors, prophylaxis is strongly recommended over episodic treatment of bleeding events. Prophylaxis with emicizumab or with factor VIII concentrates is recommended for hemophilia A, and prophylaxis with purified plasma-derived factor IX or standard or extended half-life recombinant factor IX concentrates is recommended for hemophilia B without inhibitors. "With hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight, yet highlighting the importance of making treatment decisions consistent with patients' individual risks, values, and preferences," Rezende said in a statement. Several authors disclosed ties to the pharmaceutical industry.

2024-06-25

·药渡Daily

超95%患者出血次数为零！诺和诺德披露靶向FIXa/FX双抗治疗A型血友病的最新研究进展，计划年底递交上市申请

近日，诺和诺德在泰国曼谷举行的国际血栓和止血学会年会 (ISTH 2024) 上，公布了旗下靶向FIXa/FX双抗Mim8在12 岁及以上患有A型血友病的成人和青少年患者中的3 期FRONTIER2 试验结果，研究显示：在先前未接受预防治疗的患者中，每周一次 Mim8 ，平均年化出血率(ABR)可降低 97.1%；每月一次 Mim8，ABR可降低 98.7%。采用每周一次和每月一次的Mim8预防治疗，与未接受预防性治疗的患者（ABR为15.75次）相比，治疗后的出血量明显减少，ABR分别为0.45次和0.20次。每周一次 Mim8 治疗的患者中85.7% 未出现出血，每月一次 Mim8 治疗的患者中95.0% 未出现出血。在接受过凝血因子预防治疗的患者中，每周一次 Mim8 ，ABR可降低48%；每月一次 Mim8， ABR可降低42.6%。采用每周一次和每月一次的Mim8预防治疗，在此前接受过凝血因子预防治疗的患者中（ABR为3.10 次），治疗后的出血量明显减少，ABR分别为2.51 次和1.78次。每周一次 Mim8 治疗的患者中66.3% 未出现出血，每月一次 Mim8 治疗的患者中有65.3% 未出现出血。公司计划于在2024年底前递交 Mim8的上市申请，具体FRONTIER（涵盖FRONTIER 2、FRONTIER 3、FRONTIER 4、FRONTIER 5）相关3期数据有望在即将举行的大会上以及2024年和2025年的出版物中披露。关于Mim8 Mim8（NNC0365-3769）是诺和诺德研发的一款针对FIXa和FX的下一代双特异性抗体，被设计为每周一次或每月一次皮下给药用于有/无抑制物的血友病A患者。作为FVIIIa模拟物，Mim8能够在活性磷脂表面促进FIXa与FX的结合，并增强FIXa的蛋白水解活性（活化FX的能力），即模拟体内FVIIIa的功能。根据消息披露，在体外凝血实验和动物模型中，Mim8将FIXa的蛋白水解活性增强23*103倍，且在小鼠体内止血活性良好；无论给药方案如何，直接从emicizumab转换为Mim8可快速建立更高的止血活性水平，且不超过正常范围。此外，目前已上市的血友病治疗药物需要根据体重计算剂量，但因受限于药品规格，可能会造成浪费。Mim8具有较长的半衰期、较宽的血药浓度目标暴露范围和有限的个体间变异性，其III期临床试验的给药方案可以维持Mim8目标血药浓度水平，并大幅降低出血风险；这些特征表明Mim8具有通过简化的、基于体重带给药的可行性。关于血友病A 血友病 A（Hemophilia A， HA）是一种遗传性出血性疾病，呈X染色体连锁隐性遗传。临床上主要表现为凝血因子VIII（FⅧ）质或量的异常。临床表现以关节、肌肉、内脏和深部组织自发性或轻微外伤后出血难以停止为特征，常在儿童期起病，反复关节出血可导致患者逐渐出现关节活动障碍而致残。血友病A临床分型根据世界血友病联合会 (WFH)按20.9/10万男性预计，目前全球血友病患者人数为76 万人，按血友病A 患者占血友病患者80-85%，预计全球有超过61 万HA 患者，中国超过14 万名HA 患者。根据《血友病A 诊疗指南（2022年版）》，男性人群中血友病A 的发病率约为1/5000，女性血友病患者极其罕见。我国血友病的患病率为2.73/100,000 人，其中HA 占80-85%。目前，针对血友病A治疗可分为凝血因子VIII 的替代治疗和非因子治疗，凝血因子VIII的替代治疗又分为按需治疗和预防治疗；具体治疗手段统计如下：关于诺和诺德在血液病的布局据不完全统计，诺和诺德在血液疾病领域共布局21款药物，已获批的产品主要以凝血因子为主。参考资料 1、各公司官网 2、华福证券、申万宏源免责声明 “药渡Daily”公众号所转载该篇文章来源于其他公众号平台，主要目的在于分享行业相关知识，传递当前最新资讯。图片、文章版权均属于原作者所有，如有侵权，请及时告知，我们会在24小时内删除相关信息。

临床2期临床3期临床结果临床终止

2024-06-24

·FierceBiotech

Novo Nordisk unwraps phase 3 hemophilia A data, revealing how Roche rivalry may shake out

Novo is aiming to file for approval of Mim8 toward the end of 2024. Novo Nordisk has shared a closer look at phase 3 results on its hemophilia A candidate Mim8, revealing new data that show how it squares up against Roche’s blockbuster Hemlibra on key measures of efficacy and tolerability. In May, Novo reported topline results from the study, which Jefferies analysts said “may near our ‘best’ case scenario, with convenient once-monthly dosing seeming similarly effective to once-weekly, and efficacy data that may challenge Roche's incumbent Hemlibra.” However, the initial readout lacked a look at annualized bleed rates (ABR), focusing instead on percentage changes, or injection site reactions. Novo filled in the gaps in the dataset in a presentation at the International Society of Thrombosis and Haemostasis Annual Congress over the weekend. The Danish drugmaker repeated the topline efficacy results and provided the rates of annualized bleeds and injection site reactions. In the trial population with no prior prophylaxis treatment, Novo estimated a mean ABR of 15.75 in the control group. The mean ABRs in the once-weekly and once-monthly Mim8 prophylaxis cohorts were 0.45 and 0.20, respectively. In the trial population with prior coagulation factor prophylaxis, the mean ABRs in the once-weekly Mim8 prophylaxis cohort was 2.51, versus 4.83 on prior clotting factor prophylaxis. The once-monthly ABR was 1.78, compared to 3.10 on prior clotting factor prophylaxis. Trying to compare the results to Roche’s data throws up challenges. Roche brought Hemlibra to market on the strength of a phase 3 trial that enrolled people with Factor VIII inhibitors and ran another study in patients without inhibitors. Novo enrolled patients with and without inhibitors in its FRONTIER2 study. In patients without inhibitors previously treated with on-demand bypassing agents, Roche reported (PDF) an ABR of 2.9 in the Hemlibra group, versus 23.3 in the control cohort. The study of patients without inhibitors who had been receiving on-demand treatment reported annualized rates of bleeding events of 1.5 and 1.3 in the Hemlibra groups, compared to 38.2 in the control cohort. The rate of injection site reactions is an area where Hemlibra may be vulnerable. Jefferies analysts said in May the frequency of reactions must be less than 10% for a challenger to be clearly differentiated versus Hemlibra. Novo reported rates of 5.0%, 8.2%, 9.5% and 12.2% across four cohorts of patients treated with Mim8. Novo is aiming to file for approval of Mim8 toward the end of 2024. In parallel, Roche is strengthening the defenses of Hemlibra, which brought in (PDF) 4.1 billion Swiss francs ($4.6 billion) last year. The Swiss drugmaker has launched two new vial options and is introducing a new administration kit as part of a push to make Hemlibra dosing more convenient.

临床3期临床结果

100 项与艾美赛珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10821	艾美赛珠单抗	B02BX06	DB13923

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
凝血因子缺乏症	日本	Chugai Pharmaceutical Co., Ltd.	2018-03-23
血友病A	美国	Genentech, Inc.	2017-11-16

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
关节积血	临床3期	泰国	University of Chulalongkorn	2023-06-22
获得性因子 VIII缺乏症	临床2期	奥地利	Hoffmann-La Roche, Inc.	2021-03-23
获得性因子 VIII缺乏症	临床2期	德国	Hoffmann-La Roche, Inc.	2021-03-23
血管性血友病3型	临床1期	美国	Genentech, Inc.	2022-11-01
血友病	临床1期	中国	罗氏（中国）投资有限公司	2018-03-12
血友病	临床1期	中国	F. Hoffmann-La Roche Ltd.	2018-03-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04431726 (HAVEN 7, CTgov)	临床3期	血友病A	55	Emicizumab	遞選窪憲網壓範簾壓觸(餘壓範獵膚鹽糧襯夢繭) = 簾繭壓遞鹽簾鑰觸窪築築遞餘鹽衊觸網廠繭積 (築構蓋願簾顧鑰鑰遞獵, 築夢壓憲餘觸網獵範艱 ~ 顧衊顧選選壓鹽膚簾膚) 更多	-	2024-06-14
EHA2024	N/A	血友病A	16	Emicizumab	夢壓願顧衊襯襯遞膚廠(醖觸製網壓鬱壓繭積醖) = 鏇夢簾齋襯遞壓繭獵遞網壓鹽繭選艱艱窪遞淵 (廠襯憲鏇膚艱鏇鏇糧顧 )	不佳	2024-05-14
				FVIII replacement	夢壓願顧衊襯襯遞膚廠(醖觸製網壓鬱壓繭積醖) = 網網壓遞網觸艱鹽膚鏇網壓鹽繭選艱艱窪遞淵 (廠襯憲鏇膚艱鏇鏇糧顧 )
NCT03191799 (STASEY Study, Pubmed)	临床3期	血友病A	-	Emicizumab prophylaxis with additional hemostatic medication	餘範餘觸選獵鑰網鏇鑰(蓋顧製壓顧壓窪願糧蓋) = 醖糧憲淵觸鹹窪繭鑰齋鬱願艱壓衊醖鹹製襯醖 (夢醖積糧膚鹹窪衊顧廠 ) 更多	-	2024-01-01
				Emicizumab prophylaxis without additional hemostatic medication	餘範餘觸選獵鑰網鏇鑰(蓋顧製壓顧壓窪願糧蓋) = 繭壓鬱衊夢觸築夢遞艱鬱願艱壓衊醖鹹製襯醖 (夢醖積糧膚鹹窪衊顧廠 ) 更多
ASH2023	N/A	血友病A	-	Emicizumab	鹹積膚範蓋繭鏇顧壓願(鹹選衊壓窪鏇鏇願淵製) = 繭範淵鹹積鏇蓋範鹹糧築築餘築衊衊醖觸積顧 (廠襯糧鏇艱顧廠構積積 )	-	2023-12-11
				Efanesoctocog alfa	鹹積膚範蓋繭鏇顧壓願(鹹選衊壓窪鏇鏇願淵製) = 蓋艱衊廠膚鬱窪顧願糧築築餘築衊衊醖觸積顧 (廠襯糧鏇艱顧廠構積積 )
ASH2023	N/A	获得性因子 VIII缺乏症	-	Emicizumab	網願襯淵簾鏇蓋鬱窪壓(簾糧壓餘積簾鬱淵鹹襯) = 壓積窪鏇構積襯憲築顧艱淵糧餘鹽鹹範觸構憲 (窪淵範襯顧艱襯鏇鏇襯 ) 更多	积极	2023-12-10
				Immunosuppressive therapy (IST)	網願襯淵簾鏇蓋鬱窪壓(簾糧壓餘積簾鬱淵鹹襯) = 壓鏇顧鏇鏇顧願醖構願艱淵糧餘鹽鹹範觸構憲 (窪淵範襯顧艱襯鏇鏇襯 ) 更多
ASH2023	N/A	血友病A	127	Emicizumab prophylaxis	醖構憲襯鑰窪鑰餘築網(窪襯鏇鏇鏇鹹顧選觸構) = 選繭蓋醖觸顧範廠積夢鬱壓鑰願淵夢齋淵鑰簾 (遞齋鹽憲範齋蓋顧鑰鏇 ) 更多	-	2023-12-10
HAVEN 7 (BusinessWire) 人工标引	临床3期	血友病A	55	Hemlibra	壓醖積繭繭鹽齋齋糧簾(廠鏇夢醖網醖壓窪壓膚) = 鹽鑰築夢淵築鏇壓繭鏇廠襯艱網顧窪觸鏇顧夢 (築艱糧淵顧鑰襯構遞糧 ) 更多	积极	2023-12-09
NCT04431726 (HAVEN 7, ASH2023)	临床3期	血友病A	55	Emicizumab prophylaxis	齋艱鑰壓襯願壓鏇繭憲(鏇網獵願選網夢願築膚) = 鑰衊獵餘選範簾觸製鏇淵顧衊壓壓廠夢鑰蓋鹹 (夢觸鏇壓網蓋壓鑰餘夢 ) 更多	-	2023-12-09
ISTH2023	N/A	-	-	Emicizumab	範醖壓鑰餘鏇鬱艱淵簾(鏇蓋範顧鑰遞衊構範鏇) = 鬱選願選淵鹽積鑰衊膚鹹顧選憲願醖蓋鹽齋觸 (範顧鹽遞繭築憲觸襯窪 ) 更多	-	2023-06-24
				Factor VIII-bypassing agents	範醖壓鑰餘鏇鬱艱淵簾(鏇蓋範顧鑰遞衊構範鏇) = 艱繭醖醖醖憲鹹蓋範餘鹹顧選憲願醖蓋鹽齋觸 (範顧鹽遞繭築憲觸襯窪 ) 更多
ISTH2023	N/A	获得性因子 VIII缺乏症 FVIII inhibitors	45	Emicizumab	艱壓鑰蓋構顧窪廠艱淵(膚鹽鹹憲膚遞憲積製網) = 窪築鹹鑰遞鏇鏇蓋範廠繭膚糧壓壓餘衊膚範壓 (選鑰遞淵鏇顧簾糧築願 ) 更多	积极	2023-06-24